Ziegler Meditech Equity Partners
VC Fund
Milwaukee, United States
Ziegler Meditech Equity Partners is a VC fund in Milwaukee focused on Health Care and Biotechnology. ZMEP is a limited partnership focusing on equity and equity-like investments in emerging medical device technologies. ZMEP invests globally drawing on the years of investing experience of its management team. With over 50 years of experience in medical device development and commercialization, the ZMEP management team has the ability to seek outand partner with leading entrepreneurs in the medical device field. With offices in the United States and Israel, ZMEP is positioned globally to partner with middle to late stage medical device companies showing great promise for success through commercialization.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Ziegler Meditech Equity Partners invests in
Stages Ziegler Meditech Equity Partners invests in
Countries Ziegler Meditech Equity Partners invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
1 more contact available
Investment Focus
Industry
- Health Care 2 (33%)
- Biotechnology 2 (33%)
- Mobile 1 (17%)
- Medical 1 (17%)
- Wireless 1 (17%)
Stage
- Series C 1 (17%)
- Series E 1 (17%)
- Series F 1 (17%)
- Funding Round 1 (17%)
Country
- United States 2 (33%)
- Israel 1 (17%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Donald I. Grande
Chief Administrative Officer
|
Chief Administrative Officer | Total investments: 0 | Find email | |
Eitan Machover
Team member
|
Team member | Total investments: 0 | Find email | |
Samuel Cubac
Managing Director
|
Managing Director | Total investments: 0 | Find email | |
S. Charles O’Meara
Managing Director
|
Managing Director | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Aposense
|
Aposense (formerly NST) is a clinical-stage molecular imaging and drug development company, with a pipeline of products based on its patented platform technology for targeting apoptosis (programmed cell death) in vivo. The company translating the science of Apoptosis (programmed cell death) into personalized patient care in multiple diseasecategories, including oncology, cardiology, and neurology. Targeting of this important biological process in-vivo opens opportunities for real-time clinical imaging of disease activity and targeted therapy.Aposense specializing in the development of novel drugs and utilizing membrane electrical forces for trans-membrane of macromolecule drugs, mainly siRNA. It also developed rationally-designed molecular nano-motors (MNMs), being novel small-molecule chemical entities and its translation into kinetic energy for movement within the hydrophobic membrane core.Aposense was founded in 1996 and is headquartered in Petah Tiqva, HaMerkaz, Israel. | $3M / May 23, 2010 | |
MobileAccess Networks
|
MobileAccess provides enterprise wireless network solution. MobileAccess brings the wireless signals from the outside indoors and then distributes them through a series of discreet antennas located throughout the facility. | $7M / Series F / Dec 15, 2009 | |
|
Aposense
|
Aposense (formerly NST) is a clinical-stage molecular imaging and drug development company, with a pipeline of products based on its patented platform technology for targeting apoptosis (programmed cell death) in vivo. The company translating the science of Apoptosis (programmed cell death) into personalized patient care in multiple diseasecategories, including oncology, cardiology, and neurology. Targeting of this important biological process in-vivo opens opportunities for real-time clinical imaging of disease activity and targeted therapy.Aposense specializing in the development of novel drugs and utilizing membrane electrical forces for trans-membrane of macromolecule drugs, mainly siRNA. It also developed rationally-designed molecular nano-motors (MNMs), being novel small-molecule chemical entities and its translation into kinetic energy for movement within the hydrophobic membrane core.Aposense was founded in 1996 and is headquartered in Petah Tiqva, HaMerkaz, Israel. | $7.3M / Aug 20, 2008 | |
MAKO Surgical
|
MAKO Surgical is a medical device company, markets its advanced robotic arm solution, joint specific applications for the knee and hip, and orthopedic implants for orthopedic procedures in the United States and internationally. The company offers MAKOplasty, a restorative surgical solution that enables orthopedic surgeons to treat patient specificosteoarthritic disease. It also provides robotic arm interactive orthopedic system (RIO) consisting of a tactile robotic arm utilizing an integrated bone cutting instrument; and a patient specific visualization component, which offers pre-operative and intra-operative guidance to the orthopedic surgeon, enabling tissue sparing bone removal, and accurate implant insertion and alignment.In 2011, The company was named the No.1 on the Technology Fast 500 as the fastest growing technology company by Deloitte and received the CSSEC Award for loyal, customer-focused staff members presented by the Technology Services Industry Association and ACE Award (Achievement in Customer Excellence) from MarketTools and Fast Tech Award as one of the 25 fastest growing technology companies in South Florida by South Florida Business Journal.MAKO Surgical was founded in 2004 and is headquartered in Florida, USA. | $30M / Series C / Feb 06, 2007 | |
|
Aposense
|
Aposense (formerly NST) is a clinical-stage molecular imaging and drug development company, with a pipeline of products based on its patented platform technology for targeting apoptosis (programmed cell death) in vivo. The company translating the science of Apoptosis (programmed cell death) into personalized patient care in multiple diseasecategories, including oncology, cardiology, and neurology. Targeting of this important biological process in-vivo opens opportunities for real-time clinical imaging of disease activity and targeted therapy.Aposense specializing in the development of novel drugs and utilizing membrane electrical forces for trans-membrane of macromolecule drugs, mainly siRNA. It also developed rationally-designed molecular nano-motors (MNMs), being novel small-molecule chemical entities and its translation into kinetic energy for movement within the hydrophobic membrane core.Aposense was founded in 1996 and is headquartered in Petah Tiqva, HaMerkaz, Israel. | $12M / Nov 09, 2006 | |
|
MobileAccess Networks
|
MobileAccess provides enterprise wireless network solution. MobileAccess brings the wireless signals from the outside indoors and then distributes them through a series of discreet antennas located throughout the facility. | $11M / Series E / Jun 13, 2006 |
Co-Investors
DeA Capital
2 deals together
Eurofund
2 deals together
HarbourVest Partners
2 deals together
Pitango VC
2 deals together
Pontifax
2 deals together
Aperture Venture Partners
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Ziegler Meditech Equity Partners invest in?
Ziegler Meditech Equity Partners invests primarily in Health Care, Biotechnology and Mobile startups, most often at Series C and Series E stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Ziegler Meditech Equity Partners?
Public channels for Ziegler Meditech Equity Partners include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Ziegler Meditech Equity Partners?
The team at Ziegler Meditech Equity Partners includes Donald I. Grande (Chief Administrative Officer), Eitan Machover (Team member) and Samuel Cubac (Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
